BOCA RATON, Fla., Aug. 1, 2018 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC), a wholly owned
BOCA RATON, Fla., Aug. 1, 2018 /PRNewswire/ -- Biotest Pharmaceuticals Corporation (BPC), a wholly ownedsubsidiary of Biotest US Corporation ("Biotest USA"), and a
Following this acquisition, BPC will continue to operate as Biotest Pharmaceuticals Corporation until all FDA regulatory approvals have been obtained.
"We are excited to be part of the Grifols prestigious global organization and remain steadfast on our mission to secure a quality supply of the raw materials needed to help the thousands of patients that rely on plasma based therapies," said Ileana Carlisle, BPC's Chief Executive Officer.
The plasma collected at Biotest Plasma Centers is used to manufacture critical care therapies that treat life threatening disorders in a variety of therapeutic areas.
About Biotest Pharmaceuticals Corporation
Biotest Pharmaceuticals Corporation (BPC), headquartered in Boca Raton, Florida, owns and operates plasmapheresis centers in 12 states with over 900 employees across the U.S. In 2017, BPC collected approximately 850,000 liters of plasma from its plasma centers. We are committed to continuing to serve the thousands of patients worldwide who rely on plasma-based therapies. To learn more about Biotest Pharmaceuticals, our Plasma Centers, and the difference we make in the lives of patients and the healthcare community, please visit us at www.biotestpharma.com and www.biotestplasma.com.
View original content:http://www.prnewswire.com/news-releases/biotest-pharmaceuticals-corporation-announces-acquisition-of-biotest-us-corporation-by-grifols-shared-services-north-america-inc-300690293.html
SOURCE Biotest Pharmaceuticals Corporation
Subscribe to our Free Newsletters!